These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

410 related articles for article (PubMed ID: 37342333)

  • 1. Cell metabolism-based optimization strategy of CAR-T cell function in cancer therapy.
    Li W; Pan X; Chen L; Cui H; Mo S; Pan Y; Shen Y; Shi M; Wu J; Luo F; Liu J; Li N
    Front Immunol; 2023; 14():1186383. PubMed ID: 37342333
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improving CAR-T immunotherapy: Overcoming the challenges of T cell exhaustion.
    Gumber D; Wang LD
    EBioMedicine; 2022 Mar; 77():103941. PubMed ID: 35301179
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Engineering Next-Generation CAR-T Cells: Overcoming Tumor Hypoxia and Metabolism.
    Gao TA; Chen YY
    Annu Rev Chem Biomol Eng; 2022 Jun; 13():193-216. PubMed ID: 35700528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A metabolic switch to memory CAR T cells: Implications for cancer treatment.
    Rostamian H; Fallah-Mehrjardi K; Khakpoor-Koosheh M; Pawelek JM; Hadjati J; Brown CE; Mirzaei HR
    Cancer Lett; 2021 Mar; 500():107-118. PubMed ID: 33290868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic reprogramming via an engineered PGC-1α improves human chimeric antigen receptor T-cell therapy against solid tumors.
    Lontos K; Wang Y; Joshi SK; Frisch AT; Watson MJ; Kumar A; Menk AV; Wang Y; Cumberland R; Lohmueller J; Carrizosa E; Boyerinas B; Delgoffe GM
    J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36914208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Altered cancer metabolism and implications for next-generation CAR T-cell therapies.
    Ramapriyan R; Vykunta VS; Vandecandelaere G; Richardson LGK; Sun J; Curry WT; Choi BD
    Pharmacol Ther; 2024 Jul; 259():108667. PubMed ID: 38763321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Research Progress on the Influence of Blood Tumor Microen-vironment on the Efficacy and the Adverse Reactions of CAR-T Cell Immunotherapy--Review].
    Liao CF; Lai HR; Li J
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Aug; 32(4):1290-1294. PubMed ID: 39192433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimization of metabolism to improve efficacy during CAR-T cell manufacturing.
    Zhang M; Jin X; Sun R; Xiong X; Wang J; Xie D; Zhao M
    J Transl Med; 2021 Dec; 19(1):499. PubMed ID: 34876185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor Microenvironment Immunosuppression: A Roadblock to CAR T-Cell Advancement in Solid Tumors.
    Johnson A; Townsend M; O'Neill K
    Cells; 2022 Nov; 11(22):. PubMed ID: 36429054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chimeric Antigen Receptor (CAR)-T Cell Immunotherapy Against Thoracic Malignancies: Challenges and Opportunities.
    Chen L; Chen F; Niu H; Li J; Pu Y; Yang C; Wang Y; Huang R; Li K; Lei Y; Huang Y
    Front Immunol; 2022; 13():871661. PubMed ID: 35911706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Solid Tumors Challenges and New Insights of CAR T Cell Engineering.
    Tahmasebi S; Elahi R; Esmaeilzadeh A
    Stem Cell Rev Rep; 2019 Oct; 15(5):619-636. PubMed ID: 31161552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advanced Strategies of CAR-T Cell Therapy in Solid Tumors and Hematological Malignancies.
    Liu Y; Peng C; Ahad F; Ali Zaidi SA; Muluh TA; Fu Q
    Recent Pat Anticancer Drug Discov; 2024; 19(5):557-572. PubMed ID: 38213150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Remodeling metabolic fitness: Strategies for improving the efficacy of chimeric antigen receptor T cell therapy.
    Shen L; Xiao Y; Tian J; Lu Z
    Cancer Lett; 2022 Mar; 529():139-152. PubMed ID: 35007698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Involving stemness factors to improve CAR T-cell-based cancer immunotherapy.
    Noraldeen SAM; Rasulova I; Lalitha R; Hussin F; Alsaab HO; Alawadi AH; Alsaalamy A; Sayyid NH; Alkhafaji AT; Mustafa YF; Shayan SK
    Med Oncol; 2023 Oct; 40(11):313. PubMed ID: 37779152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells.
    Elahi R; Khosh E; Tahmasebi S; Esmaeilzadeh A
    Front Immunol; 2018; 9():1717. PubMed ID: 30108584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coengineering specificity, safety, and function into T cells for cancer immunotherapy.
    Giordano Attianese GMP; Ash S; Irving M
    Immunol Rev; 2023 Nov; 320(1):166-198. PubMed ID: 37548063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Befriending the Hostile Tumor Microenvironment in CAR T-Cell Therapy.
    Lindo L; Wilkinson LH; Hay KA
    Front Immunol; 2020; 11():618387. PubMed ID: 33643299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Engineering CAR-T Cells for Next-Generation Cancer Therapy.
    Hong M; Clubb JD; Chen YY
    Cancer Cell; 2020 Oct; 38(4):473-488. PubMed ID: 32735779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relapse after CAR-T cell therapy in B-cell malignancies: challenges and future approaches.
    Gu T; Zhu M; Huang H; Hu Y
    J Zhejiang Univ Sci B; 2022 Oct; 23(10):793-811. PubMed ID: 36226535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulating tumor physical microenvironment for fueling CAR-T cell therapy.
    Luo Z; Yao X; Li M; Fang D; Fei Y; Cheng Z; Xu Y; Zhu B
    Adv Drug Deliv Rev; 2022 Jun; 185():114301. PubMed ID: 35439570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.